While immunotherapies have revolutionized cancer treatment, they are currently effective only for a small subset (from 20% to 30%) of patients. Tel-Aviv-based Nucleai is developing AI software for image analysis and modeling of pathology data to assist in the development of more effective drugs. The long-term goal of the 3-year-old startup is to be "a leader in precision medicine," says its co-founder and CEO, Avi Veidman. Nucleai's team has more than 50 years of cumulative AI experience gained in the Israeli Intelligence Corps--including satellite image analysis--plus the expertise of physicians and healthcare professionals, resulting in a multi-disciplinary approach to the challenge of ineffective predictive biomarkers. To find a better answer, "we combine different sources of information, just like what we did in intelligence," says Veidman. "The cancer does not care about your specialty," he observes.